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Aims The preliminary evidence supports an association between obstructive sleep apnoea (OSA), disturbed cardiac repo-
larization, and consequent cardiac dysrhythmias. The aim of the current trial was to assess the effects of continuous
positive airway pressure (CPAP) therapy withdrawal on the measures of cardiac repolarization in patients with OSA.
Methods
and results
Forty-one OSA patients established on CPAP treatment were randomized to either CPAP withdrawal (subtherapeu-
tic CPAP) or continue therapeutic CPAP for 2 weeks. Polysomnography was performed, and indices of cardiac repo-
larization (QTc, TpTec intervals) and dispersion of repolarization (TpTe/QT ratio) were derived from 12-lead
electrocardiography (ECG) at baseline and 2 weeks. Continuous positive airway pressure withdrawal led to a recur-
rence of OSA. Compared with therapeutic CPAP, subtherapeutic CPAP for 2 weeks was associated with a significant
increase in the length of the QTc and TpTec intervals (mean difference between groups 21.4 ms, 95% CI 11.3–1.6 ms,
P, 0.001 and 14.4 ms, 95% CI 7.2–21.5 ms, P, 0.001, respectively) and in the TpTe/QT ratio (mean difference
between groups 0.02, 95% CI 0.00–0.03, P ¼ 0.020). There was a statistically significant correlation between
the change in apnoea/hypopnoea index (AHI) from baseline, and both the change in the QTc interval and the
TpTec interval (r ¼ 0.60, 95% CI 0.36–0.77, P, 0.001 and r ¼ 0.45, 95% CI 0.17–0.67, P ¼ 0.003, n ¼ 41,
respectively).
Conclusion Continuous positive airway pressure withdrawal is associated with the prolongation of the QTc and TpTec intervals
and TpTe/QT ratio, which may provide a possible mechanistic link between OSA, cardiac dysrhythmias, and thus
sudden cardiac death.
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Introduction
Obstructive sleep apnoea (OSA) is a highly prevalent sleep-related
breathing disorder affecting up to 30% of middle-aged adults.1,2
Obstructive sleep apnoea is characterized by the repetitive inter-
ruption of ventilation during sleep caused by the collapse of the
upper airway, resulting in apnoeas and hypopnoeas associated
with oxygen desaturations and arousals from sleep. As a conse-
quence of the fragmented sleep, patients with OSA may suffer
from increased daytime sleepiness leading to impaired quality of
life and the increased risk of traffic accidents.3,4
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Symptomatic OSA has been implicated as an important factor in
the pathogenesis of hypertension and cardiovascular disease.4–6
Furthermore, the findings of observational studies suggest that
OSA may be causally related with cardiac dysrhythmias, such as
premature ventricular contractions, atrial fibrillation (AF),
ventricular arrhythmias, atrioventricular block, and sinus arrest.7–
12 The observation that patients with OSA have an increased
risk of sudden cardiac death (SCD) at night suggests an association
between OSA and SCD.12 The mechanistic link between OSA and
SCD, however, has not yet been thoroughly established. An
increase in the dispersion of cardiac repolarization has been sug-
gested as a potential mechanism of ventricular arrhythmias and
SCD.13–15 The various markers derived from the surface electro-
cardiography (ECG) as well as from the electrophysiological
studies provide information about the transmural dispersion of
repolarization and the electrical inhomogeneity in the ventricles
during repolarization.16–18
There is preliminary evidence from uncontrolled studies sug-
gesting that cardiac repolarization is prolonged and the transmural
dispersion of repolarization is increased, in patients with OSA.
These ECG abnormalities seem to reverse with continuous posi-
tive airway pressure (CPAP) treatment.19 However, there is no
data from randomized controlled interventional trials proving this
association, and thus a controversy remains as to whether OSA
is an independent aetiologic risk factor for disturbed cardiac
repolarization.11
To address this uncertainty, we have analysed the ECG data
from a randomized controlled trial exploring the effects of a
2-week CPAP withdrawal vs. continuing CPAP in patients with
previously treated OSA,20 in order to investigate the effects of
CPAP withdrawal and a return of OSA on ECG-derived measures
of cardiac repolarization.
Methods
Patients, trial design, and sample calculation
Patients previously diagnosed with OSA, and treated with CPAP, who
were registered in a database of the Sleep Disorders Centre and
Pulmonary Division of the University Hospital of Zurich, Switzerland,
were eligible for the trial if they were aged between 20 and
75 years, had an oxygen desaturation index (ODI, ≥4% dips) of
.10/h during their initial sleep study, an ODI of .10/h during an
ambulatory nocturnal pulse-oximetry performed on the last night of
a four-night period without CPAP prior to the main study, and if
they had been treated with CPAP for .12 months with a average
compliance of ≥4 h per night.
Patients with previous ventilatory failure, Cheyne–Stokes breathing,
unstable and untreated coronary or peripheral artery disease, severe
and inadequately controlled arterial hypertension, a history of any
sleep-related accident, or with a heavy goods vehicle driver’s licence,
were excluded from the study. The trial was performed according to
the Declaration of Helsinki, was approved by the University Hospital
of Zurich research ethics committee (EK-1600) and registered
(ISRCTN 93153804). Written informed consent was obtained from
all participants. The primary outcomes of this trial [change in the
ODI and apnoea/hypopnoea index (AHI)] are reported elsewhere in
more detail.20
After confirming the persistence of OSA by home overnight
pulse-oximetry at the end of a four-night period without CPAP, eligible
patients returned to therapy with CPAP for ≥7 days. After baseline
assessments, the patients were randomized to either continue with
CPAP therapy or switch to subtherapeutic CPAP for 2 weeks by a
series of presealed and numbered envelopes. The follow-up assess-
ments of ECG were performed at 1 and 2 weeks. Patients remained
blinded as to whether they were receiving therapeutic or subtherapeu-
tic CPAP, as did the investigators. The member of the research team
who randomized the patients did not take part in the outcome
assessments.
A sample size estimation was performed based on the assumption
that a clinically relevant difference in the ODI (≥4% drop of oxygen
saturation/h) between active treatment and placebo is 10/h (SD 10)
and a clinically relevant difference in the QTc is 20 ms (SD 15).
21
Based on these assumptions, the power calculation indicated that 41
patients were required in total in order to not miss clinically relevant
differences in the ODI (with a power of 90%) and in the QTc (with a
power of 99%).
Sleep studies and continuous positive airway
pressure
At baseline and 2 weeks, attended polysomnographic sleep studies
were performed and analysed according to the standard methods.
Apnoeas were defined as a reduction in the amplitude of chest wall
motion by .90% from baseline over the previous 2 min for .10 s,
hypopnoeas were defined as a reduction in the amplitude of chest
wall motion by .50% from baseline over the previous 2 min for
.10 s, associated with a ≥4% drop in oxygen saturation.22 The
severity of sleep-disordered breathing was quantified as the number
of apnoeas/hypopnoeas (AHI) and oxygen desaturations ≥4% per
hour of study (ODI). In patients randomized to subtherapeutic CPAP,
the subtherapeutic pressure was achieved by setting the CPAP
machine to the lowest pressure, inserting a flow-restricting connector
at the machine outlet, and inserting six extra holes in the collar of the
main tubing at the end of the mask to allow air escape, thus preventing
rebreathing of carbon dioxide, as previously described.23 Sleepiness was
assessed using the Epworth sleepiness score (ESS).24,25
Electrocardiography
The participants were asked to abstain from alcohol, tobacco, or
caffeine on the day the measurements were done. The room tempera-
ture and lighting were set at the same level for all measurements. The
participants rested for 5 min in the supine position before measure-
ments were done. For all electrocardiographic recordings a commer-
cially available 12-lead ECG (AT 104 PC, Schiller-Reomed AG,
Switzerland) was used and set at 25-mm/s paper speed and 10-mm/
mV amplitude. The measurements of the ECG intervals were per-
formed in duplicate with a dedicated ECG analysis software
(DatInfw Measure 2.1d, DatInf GmbH, Tu¨bingen, Germany) by two
investigators who were blinded to the patient’s group allocation. The
mean of the measurements by the two investigators was used for stat-
istical analysis. Lead V5 was used and when unsuitable, lead V4 or V6.
The indices of cardiac repolarization were determined as follows: the
QT interval was defined as the time from the earliest onset of the QRS
complex to the point at which the downward slope of the T-wave
returned to baseline and the Tpeak-to-Tend interval (TpTe) as the
time from the peak of the T-wave to the end of the T-wave.26 The
end of the T-wave was defined as the cutting point of the tangent to
the downward slope of the T-wave and the isoelectric line.18 Both
the QT and TpTe intervals were corrected for the heart rate as
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described previously.27 As a measure of dispersion of repolarization,
TpTe/QT ratio was calculated.14
Data analysis
All values are presented as mean (SD) unless otherwise stated. Statis-
tical analysis was performed with Statistica V6.0 (StatSoft, Tulsa, OK,
USA). Differences in baseline characteristics between the groups
were assessed by independent t-tests and x2 tests as appropriate.
Comparisons of changes between groups were assessed by inde-
pendent t-tests and Mann–Whitney U tests as appropriate. The
analyses were performed on an intention-to-treat basis with no
change assumed for the missing follow-up data. Correlations
between changes in the indices of OSA severity and the ECG measures
of cardiac repolarization were assessed by Pearson correlation
coefficients. A two-sided P value of ,0.05 was considered to be stat-
istically significant.
Results
Trial profile and patient characteristics
Figure 1 shows the trial profile. The two groups were similar
regarding all patients’ characteristics at baseline (Table 1). Data
on AHI downloaded from the patients’ CPAP machines, as well
as ESS values within the normal range, proved successful treatment
of patients with CPAP prior to the study (Table 1). One patient in
the subtherapeutic CPAP group withdrew from the study 4 days
after randomization because of intolerable daytime symptoms.
Figure 1 Trial profile.
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Sleep-disordered breathing and sleepiness
Compared with therapeutic CPAP, AHI increased significantly with
the subtherapeutic CPAP at 2 weeks (mean difference in the AHI
change 30.2, 95% CI 18.8–41.7) and ODI (mean difference in the
ODI change 24.0, 95% CI 13.5–34.4, P, 0.001 for both compar-
isons). ESS increased significantly at 2 weeks in the subtherapeutic
group compared with the therapeutic group (mean difference in
ESS change 3.1, 95% CI 1.4–4.7, P, 0.001, Table 2).
Effect of continuous positive airway
pressure withdrawal on cardiac
repolarization indices
ECG interval times at baseline, and changes from baseline, are
shown in Table 3. There were no relevant differences between
the two groups at baseline.
Compared with therapeutic CPAP, subtherapeutic CPAP for 2
weeks was associated with a significant increase in the length of
the QTc and TpTec intervals (mean difference 21.4 ms, 95%
CI 11.3–31.6 ms, P, 0.001 and 14.4 ms, 95% CI 7.2–21.5 ms,
P, 0.001, respectively) (Figures 2 and 3) and in the TpTe/QT
ratio (mean difference 0.02, 95% CI 20.00–0.03, P ¼ 0.020).
A statistically significant correlation was observed between the
change in the AHI, and both the changes in the QTc and the
TpTec intervals (r ¼ 0.60, 95% CI 0.36–0.77, P, 0.001 and r ¼
0.45, 95% CI 0.17–0.67, P ¼ 0.003, respectively, n ¼ 41, Figures 4
and 5).
A statistically significant correlation was also found between the
change in the ODI, and both the changes in the QTc and the TpTec
intervals (r ¼ 0.44, 95% CI 0.16–0.66, P ¼ 0.004, and r ¼ 0.51,
95% CI 0.24–0.71, P, 0.001, respectively, n ¼ 41).
Discussion
This is the first randomized controlled trial providing data on the
effects of OSA on ECG measures of cardiac repolarization. We
found that CPAP withdrawal was associated with a considerable
prolongation and an increase in the dispersion of cardiac repolar-
ization. These findings provide further evidence suggesting a
possible link between OSA, cardiac dysrhythmias, and SCD.
The QT interval represents the electrocardiographic correlate
of ventricular de- and repolarization, including the vulnerable
period for reentry tachycardia. As such, numerous studies have
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Table 2 Effects of continuous positive airway pressure withdrawal on sleep-disordered breathing and sleepiness
Baseline Change from baseline 95% CI between
groups
P-value
Therapeutic CPAP
(n5 20)
Subtherapeutic CPAP
(n 5 21)
Therapeutic CPAP
(n5 20)
Subtherapeutic CPAP
(n 5 21)
AHI (1/h) 1.7 (1.8) 2.2 (2.5) 0.4 (2.8) 30.6 (25.2) 18.8/41.7 ,0.001
ODI (1/h) 0.5 (0.8) 0.9 (2.0) 20.2 (1.0) 23.8 (23.1) 13.5/34.4 ,0.001
ESS 7.4 (3.1) 6.6 (2.7) 20.9 (2.2) 2.2 (2.9) 1.4/4.7 ,0.001
Values are mean (SD). 95% CI ¼ 95% confidence interval of the difference between groups in change from baseline.
AHI, apnoea/hypopnoea index; ODI, oxygen desaturation index; ESS, Epworth sleepiness score.
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Table 1 Baseline characteristics
Therapeutic
CPAP
(n 5 20)
Subtherapeutic
CPAP
(n 5 21)
Age (years) 63.6 (5.1) 61.8 (7.5)
Females (n) 1/20 0/21
Body mass index (kg/m2) 32.9 (6.5) 33.1 (4.4)
Waist/hip circumference ratio 1.0 (0.1) 1.0 (0.0)
Neck circumference (cm) 46.4 (3.7) 46.1 (4.2)
Current smokers (n) 1/20 4/21
Ex-smokers (n) 5/20 8/21
Hypertension (n) 14/20 17/21
Diabetes (n) 4/20 5/21
CAD (n) 2/20 1/21
Sokolow–Lyon index (mV) 21.1 (5.3) 21.1 (5.7)
Cardiac dysrhythmiaa (n) 0/20 1/21
Antihypertensive medication (n) 13/20 16/21
Beta-blockers (n) 7/20 6/21
Diuretics (n) 5/20 8/21
Cholesterol-lowering
medication (n)
7/20 7/21
Glucose-lowering medication (n) 3/20 2/21
Potassium (mmol/L) 3.9 (0.4) 3.9 (0.3)
AHI original sleep study 36.0 (17.3) 45.3 (22.3)
ODI original sleep study 26.6 (13.5) 37.3 (22.7)
ODI 4-day withdrawal 25.4 (8.6) 28.9 (16.2)
AHI on CPAPb 5.1 (2.7) 4.3 (2.3)
CPAP compliance (min) 373.1 (67.9) 362.8 (72.3)
CPAP use relative to time in
bed (%)c
80.8 (14.5) 79.2 (20.0)
Duration of CPAP treatment
(years)
5.6 (3.4) 7.4 (3.2)
ESS before therapy 7.4 (3.1) 6.6 (2.7)
Time from screening to
randomization (days)
75.9 (29.0) 68.3 (29.9)
Values are mean (SD) where applicable.
CAD, coronary heart disease; AHI, apnoea/hypopnoea index; ODI, oxygen
desaturation index; AHI on CPAP, AHI downloaded from CPAP machine averaged
from previous 6 months; ESS, Epworth sleepiness score.
aAtrial fibrillation.
bDerived from CPAP machine.
cTime in bed estimated by actimetry.
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identified the inherited as well as acquired QT prolongation as a
risk factor for the occurrence of malignant cardiac dysrhythmias
and SCD.28,29
The Tpeak-to-Tend (TpTe) interval is a measure of cardiac
transmural dispersion of repolarization, which is explained by a
gradient of action potential duration from endo- (longest) to
epicardial cells (shortest).30,31 A prolongation of the TpTe interval
leads to increased vulnerability for the occurrence of early after-
depolarizations and has been associated with ventricular tachy-
cardia and an increased risk for SCD.32–34 Specifically, recent
findings from Panikkath et al.33 suggest that patients with an uncor-
rected TpTe interval .100 ms in the resting ECG are at increased
risk of SCD.
In the current study, QTc and TpTec intervals at baseline were
already considerably longer in the CPAP-treated study population
than in a group of healthy young adults in one of our previous
studies35 (416.1 vs. 403.8 and 114.7 vs. 87.3 ms, respectively)
possibly due to a high rate of comorbidities seen in our OSA popu-
lation. However, we found that CPAP withdrawal for 2 weeks was
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Effect of continuous positive airway pressure withdrawal on the electrocardiographic intervals and urinary
norepinephrine
Baseline Change from baseline 95% CI
between
groups
P-value
Therapeutic
CPAP (n5 20)
Subtherapeutic
CPAP (n5 21)
Therapeutic
CPAP (n5 20)
Subtherapeutic
CPAP (n5 21)
RR (ms) 962.2 (180.2) 892.8 (205.4) 246.9 (111.5) 254.7 (195.7) 292.2/108 0.875
P (ms) 108.5 (15.3) 110.6 (16.2) 23.3 (34.7) 8.1 (46.2) 214.5/37.3 0.379
PQ (ms) 196.7 (25.2) 181.1 (26.3) 21.8 (18.4) 22.9 (11.7) 210.8/8.6 0.824
QRS (ms) 106.4 (25.6) 101.0 (13.7) 0.9 (15.9) 1.1 (11.2) 28.4/8.9 0.960
QT (ms) 416.8 (38.5) 389.1 (39.2) 211.5 (38.6) 9.0 (18.7) 1.5/39.5 0.035
QTc (ms)
a 421.9 (16.0) 416.1 (28.0) 20.1 (9.3) 21.3 (20.4) 11.3/31.6 ,0.001
TpTe (ms) 108.8 (14.4) 104.3 (12.6) 22.4 (10.7) 9.6 (10.9) 7.0/16.9 0.001
TpTec (ms)
a 111.8 (14.5) 114.7 (14.6) 0.5 (11.3) 14.9 (11.3) 7.2/21.5 ,0.001
TpTe/QT 0.26 (0.03) 0.27 (0.04) 0.00 (0.03) 0.02 (0.03) 20.00/0.03 0.020
Norepinephrine
(nmoL/mmoL)
22.1 (11.5) 26.3 (10.2) 0.9 (5.4) 11.5 (15.5) 2.5/18.7 0.012
Values are mean (SD).
95% CI ¼ 95% confidence interval of the difference between groups in change from baseline. N ¼ 17 and 18 for urinary norepinephrine (nmoL/mmoL of creatinine) in the
therapeutic and subtherapeutic CPAP group, respectively.
aHeart-rate corrected.
Figure 2 Data are presented as mean and standard error. Black
bars represent the subtherapeutic continuous positive airway
pressure group and white bars represent the therapeutic continu-
ous positive airway pressure group. There was a significant
increase in the length of the QTc at 2 weeks in the subtherapeutic
continuous positive airway pressure group compared with the
therapeutic continuous positive airway pressure group.
*P, 0.001 for comparisons of changes from baseline between
groups.
Figure 3 Data are presented as mean and standard error. Black
bars represent the subtherapeutic continuous positive airway
pressure group and white bars represent the therapeutic continu-
ous positive airway pressure group. There was a significant in-
crease in the length of the TpTec at 2 weeks in the
subtherapeutic continuous positive airway pressure group com-
pared with the therapeutic continuous positive airway pressure
group. *P, 0.001 for comparisons of changes from baseline
between groups.
V.A. Rossi et al.2210
associated with further, statistically significant prolongation of the
QTc and TpTec intervals. The withdrawal of CPAP was also asso-
ciated with an increase in the uncorrected mean TpTe interval
from 104 to 114 ms; as a result, 71% of patients in the subthera-
peutic CPAP group were shifted to TpTe values .100 ms and
55% were shifted to QTc values .430 ms. Since these cut-offs
were previously associated with an elevated risk for SCD,33 our
data imply that many OSA patients without CPAP treatment
may fall into this category. Moreover, our data demonstrate an
increase in the effect of CPAP withdrawal on cardiac repolarization
parameters across 2 weeks (Figures 2 and 3), indicating that further
withdrawal may result in an even more pronounced increase in
these values.
The increase in the length of the QTc and TpTec intervals was
positively correlated with the change in the severity of sleep-
disordered breathing (Figures 4 and 5) suggesting that the risk for
SCD increases with the severity of OSA. There is also preliminary
data from uncontrolled studies in patients with OSA showing that
QT intervals are longer during the night-time compared with the
daytime,21 and longer at the onset of an apnoea episode compared
with the period after an apnoea.36 In an observational study, OSA
has been shown to be associated with the increased QT interval
variability during sleep, possibly reflecting alterations in the sympa-
thetic outflow to the ventricular myocardium.37
In addition to the prolonged QTc and TpTec intervals, an
increased TpTe/QT ratio, a measure of disproportional prolonga-
tion of global dispersion relative to the QT interval, may have an
important role in arrhythmogenesis.16 This ratio has the advantage
of more reliably eliminating the confounding effects of the heart
rate variability in the ECG and the inter-individual variation in
the length of the QT interval.14 We were able to demonstrate
an increase in the TpTe/QT ratio after CPAP withdrawal, further
substantiating a potential risk for arrhythmias in this situation.
These findings are in line with the preliminary evidence from
observational studies, suggesting that the severity of OSA is also
associated with the worsening of QT dynamicity parameters
(QT/RR slope), an indicator of abnormal rate adaption of
ventricular repolarization.19,37 This may be due to a relative lack
of parasympathetic tone in patients with OSA and, thus, be a
predictor of myocardial vulnerability and tendency to cardiac
dysrhythmias.19,38
A prolongation of QRS duration, i.e. a prolongation of
ventricular depolarization, has been suggested to be associated
with an increased propensity for SCD.39 In our study, we found
a small increase in QRS duration in the CPAP withdrawal group,
which was, however, not statistically significant (1.1 ms, P ¼
0.96). The risk of SCD associated with QRS prolongation is
mainly interpreted as a result of overt coronary artery disease
(ischaemia or scar).40,41 However, in our study population, only
three patients (two in the CPAP group and one in the CPAP with-
drawal group) had (stable) coronary artery disease. Thus the
chances of finding a significant prolongation of the QRS complex
during the CPAP withdrawal were likely to be much smaller than
it would have been in patients with overt coronary heart
disease. This is in contrast to the more subtle markers of repolar-
ization such as TpTec. It hence remains unclear at present whether
OSA directly affects ventricular depolarization in the longer term,
and further studies are required to conclusively answer this
question.
There may be several mechanisms explaining the disturbance of
repolarization and the high incidence of atrial and ventricular dys-
rhythmias and SCD in OSA patients. Obstructive apnoea and
hypopnoea are associated with repeated inspiratory efforts
against the collapsed upper airways associated with large swings
in the intrathoracic pressure, which may be as high as 60–
80 mmHg. During each obstructive apnoea and hypopnoea, the
Figure 5 Correlation between the change in the TpTec interval
(change from baseline to 2 weeks) and change in the apnoea/
hypopnoea index (r ¼ 0.45, 95% CI 0.17–0.67, P ¼ 0.003,
n ¼ 41). Black circles represent patients in the subtherapeutic
continuous positive airway pressure group and white circles rep-
resent patients in the therapeutic continuous positive airway
pressure group.
Figure 4 Correlation between the change in the QTc interval
(change from baseline to 2 weeks) and change in the apnoea/
hypopnoea index (r ¼ 0.60, 95% CI 0.36–.77, P, 0.001,
n ¼ 41). Black circles represent patients in the subtherapeutic
continuous positive airway pressure group and white circles rep-
resent patients in the therapeutic continuous positive airway
pressure group.
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negative intrathoracic pressure exerts a direct distending force on
the heart and aorta.42 Cardiac wall stress is additionally augmented
by considerable acute changes in the atrial and ventricular volume
during obstructive apnoea and hypopnoea.43–45 In vitro experi-
ments on myocardial tissue have shown that acute atrial stretch
(similar to the atrial stretch occurring during apnoea/hypopnoea)
induces both early and delayed after-depolarizations which may
trigger premature myocardial contractions.44,45 In an animal
model, Linz et al.46 reported shortening of the right atrial refrac-
tory period and the increased susceptibility to premature beats
and AF induced by negative thoracic pressure during obstructive
respiratory events. This mechanism, repeated during each
apnoeic phase, may lead in the long-term to the electrical and
mechanical remodelling of both the atria and left ventricle,47,48
thereby possibly explaining the high prevalence of AF in patients
with OSA.49,50
A further possible mechanism for the alteration of cardiac repo-
larization may be autonomic nervous system imbalance which has
been shown to be present in OSA patients.6 Baumert et al.51
showed that experimentally induced increased cardiac sympathetic
activity is positively correlated with QT variability in hypertensive
patients. We previously reported an increased sympathetic activity
as assessed by the urinary noradrenaline (mean increase 43.7%)
and heart rate (mean increase 9.7%) after 2 weeks of CPAP with-
drawal in the current study population.20 In addition, there was a
correlation between the change in the QTc and change in the
heart rate (r ¼ 0.45, P ¼ 0.003, data not shown) as well as
between the change in the QTc and change in the urinary
noradrenaline levels (r ¼ 0.37, P ¼ 0.020, data not shown). These
findings suggest that increased sympathetic nervous system activity
may be one of the underlying mechanisms between OSA and the
increased dispersion of cardiac repolarization, but further studies
are warranted.
In summary, the increased susceptibility to dysrhythmias may
therefore be explained by structural remodelling (resulting in the
formation of an arrhythmogenic substrate),48 electrical remodelling
(manifesting as disturbed repolarization), increased sympathetic
activation, and triggers (including acute episodes of apnoea and
hypopnoea), which may eventually lead to the onset of ventricular
dysrhythmias (Coumel’s triangle).47
The current study has some inherent limitations. We per-
formed standard resting 12-lead ECG and not continuous 24-h
ECG, thus it is not possible to determine from the current
study, the effects of CPAP withdrawal on ECG for longer
periods, or during sleep. Therefore, further data from rando-
mized controlled studies are needed to evaluate the effect of
CPAP on measures of repolarization during sleep and longer
daytime periods. Future interventional studies will also need to
address the question as to which mechanisms underpin the asso-
ciation between OSA and both the prolongation and the
increased dispersion of cardiac repolarization. The question as
to whether OSA is associated with chronic and irreversible
alterations of the ECG will need to be addressed in future
trials with conventional design, however, due to ethical issues
related to a long-term control group, it will be very difficult to
perform a randomized controlled trial to answer this question.
In addition, the findings of a study that selects patients with
high CPAP compliance cannot be generalized without caution
to the untreated OSA population usually seen in a sleep clinic.
In conclusion, we have found that CPAP withdrawal for 2 weeks
was associated with prolongation as well as increased dispersion of
cardiac repolarization. These findings may provide a possible
mechanistic link between OSA, cardiac arrhythmias, and SCD.
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